Recent Updates
Recently added Catalysts
ACET Positive Sentiment

Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Adicet Bio, a clinical stage biotechnology company, announced that its CEO, Chen Schor, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14-16, 2026, in New York, showcasing the company's advancements in CAR-T therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Adicet Bio is actively participating in a prominent investment conference.
  • The event provides a platform for discussing innovative therapies.
  • Involvement in the conference highlights the company's growth potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~17 mo
Low dilution risk
Lead asset
ADI-212
Phase 1 · PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference being held from September 14-16, 2026, in New York.Details o

Frequently Asked Questions

What is the purpose of the conference?

The conference aims to provide a platform for discussing investment opportunities and innovations in biotechnology.

Who will represent Adicet Bio at the conference?

Chen Schor, the President and CEO of Adicet Bio, will participate in the fireside chat.

When is the H.C. Wainwright conference scheduled?

The conference will be held from September 14-16, 2026, in New York.

What does Adicet Bio specialize in?

Adicet Bio focuses on developing allogeneic gamma delta CAR-T cell therapies for various diseases.

ShareAdd on Google
Tags: ACET Viatris Investor Conferences Healthcare Adicet Bio H.C. Wainwright investment conference CAR-T therapies
Last updated: Sep 2, 2026

Biotech snapshot

Cash runway
$118M liquidity · $7M/mo burn
~17 mo
Low dilution risk
Lead asset
ADI-212Phase 1
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) →